ClinicalTrials.gg
Not yet recruitingNCT07711756ObsATBGignaUrgUpdated Jul 17, 2026

Comparative Study of Adherence to Antibiotic Therapy Among Pediatric Patients: Hospital Emergency Department vs. Primary Care Center

An observational study in Tonsillitis Acute, Pneumonia - Bacterial and Otitis Media Acute, sponsored by University Hospital, Montpellier. Not yet recruiting. Open to participants aged 3 Months to 16 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by University Hospital, Montpellier · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
191
Ages
3 Months to 16 Years
Sex
All
01

Study summary

This study was initiated because of the limited litterature available on this topic. The objective was to compare adherence to antibiotic therapy among a pediatric population treated in two healthcare settings in France: the Gignac Health Center, a primary care facility, and the Pediatric Emergency Department of Montpellier University Hospital. This observational study assessed treatment adherence through a telephone questionnaire administered to parents after the theorical end of the treatment.

02

Conditions studied

  • Tonsillitis Acute
  • Pneumonia - Bacterial
  • Otitis Media Acute
  • Cystitis Acute
  • Sinusitis Bacterial
  • Pneumonia Atypical
  • Impetigo

Keywords

  • compliance - antibiotic - pediatric
03

In context

Pneumonia, Bacterial

153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.

This study's planned enrollment of 191 is below the median of 224 across 39 observational studies indexed under Pneumonia, Bacterial.

Browse Pneumonia, Bacterial studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,261 studies on the registry; 224 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patients presenting to the Gignac Primary Care Health Center or the Pediatric Emergency Department of Montpellier University Hospital with a suspected bacterial infection and considered eligible for an outpatient oral antibiotic prescription.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 3 months to 16 years
  • Receiving an outpatient oral antibiotic prescription
  • Diagnosed with an acute bacterial infection

Exclusion criteria

Exclusion Criteria:

  • Unemancipated minors presenting without a parent or legal guardian.
  • Participation in another clinical research study with an ongoing exclusion period
  • Refusal to participate after the reflection period
  • Parents unable to understand the study information (e.g., language barrier or cognitive impairment)
  • Not affiliated with, or not a beneficiary of, a national health insurance scheme
  • Pregnant or breastfeeding female participants
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
191 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pediatric patients prescribed antibiotic for acute bacterial infection at the Gignac Health center

    Pediatric patients aged 3 months to 16 years presenting with an acute bacterial infection and prescribed an outpatient antibiotic treatment were eligible for inclusion. Parents were contacted by telephone between 15 and 21 days after the antibiotic prescription to assess treatment adherence.

  • Children prescribed antibiotic for acute bacterial infection at pediatric emergency of Montpellier

    Pediatric patients aged 3 months to 16 years presenting with an acute bacterial infection at pediatric emergency department Montpellier University Hospital and prescribed an outpatient antibiotic treatment were eligible for inclusion. Parents were contacted by telephone between 15 and 21 days after the antibiotic prescription to assess treatment adherence.

06

What researchers measure

Primary outcomes

  1. Proportion of patients who adhered to the antibiotic prescription provided by the general practitioner (GP) or the emergency physician (University Hospital)

    Treatment adherence was considered satisfactory when at least 80% of the prescribed antibiotic course was taken

    Time frame: The study period extended from the initial consultation (antibiotic prescription) to 21 days after the prescription, depending on the prescribed treatment duration.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Aug 2028, 23 months later.

Of 22 observational studies under Pneumonia, Bacterial, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 17, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07711756
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Aug 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Jul 17, 2026

Study contacts

Eric E JEZIORSKI, Professor of Medicine
Contact
e-jeziorski@chu-montpellier.fr
+33627383451
Eric E JEZIORSKI, Professor of Medicine at Montp
study director · Pediatric Emergency Department, Montpellier University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion